{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-043485","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2025-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.552830+00:00","generated_at":"2026-05-24T06:57:24.945972+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Lexeo Q4 net loss $25.9M; FDA aligns on LX2006 accelerated path; LX2020 shows protein expression increases","bullets":["Net loss $25.9M ($0.78/sh) for Q4 2024 vs $14.2M; FY net loss $98.3M ($3.09/sh) vs $66.4M.","Cash $128.5M expected to fund operations into 2027.","FDA agrees to use frataxin expression increase from baseline as co-primary endpoint for LX2006 pivotal study.","LX2020 cohort 1: PKP2 protein increased 71% and 115% from baseline; first participant saw 67% PVC reduction.","LX2020 cohort 2 fully enrolled; interim clinical data expected H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-043485","json":"https://secwatch.observer/filing/0000950170-25-043485.json","markdown":"https://secwatch.observer/filing/0000950170-25-043485.md","text":"https://secwatch.observer/filing/0000950170-25-043485.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025043485/0000950170-25-043485-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017025043485/lxeo-20250324.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:57:24.945972+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}